PGI9 COST-EFFECTIVENESS OF ESOMEPRAZOLE VERSUS GENERIC OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX ESOPHAGITIS IN SWEDEN  by Wahlqvist, P & Sörngård, H
A121Abstracts
column® treatment of moderate severe UC and CD patients is
associated with cost offsets for surgery, hospitalizations, outpa-
tient care and drugs and an increase of QALYs. The cost-effec-
tiveness ratios remain within the acceptable range for treatments
to be recommended for use in Sweden.
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OBJECTIVES: To assess cost-effectiveness of esomeprazole 
40mg (SEK 14.68 / tablet: EUR 1 = SEK 9.27, June 15, 2005)
once daily (od) versus omeprazole 20mgod at the lowest avail-
able generic drug price (SEK 4.32 / tablet) in the acute treatment
of reﬂux esophagitis (RE) in Sweden. METHODS: A decision
analysis model was used considering pooled effectiveness data
from comparative clinical studies and patient management
assumptions based on expert opinions. Results were analysed
using an 8-week time horizon and reported separately including
work productivity costs or direct medical costs (drugs, physician
contacts, investigations) only. Utility values associated with
having healed RE (0.84) or unhealed RE (0.69) were derived
from a study using the rating scale method in patients with
gastro-esophageal reﬂux disease (GERD). Estimates of GERD-
related work productivity loss (absence from work and reduced
productivity while at work) were derived from observed differ-
ences in productivity before and after treatment in another study.
A probabilistic sensitivity analysis (PSA) on direct medical 
costs was used to assess robustness of results, along with addi-
tional analyses extending the time horizon beyond 8 weeks. An
acceptable threshold of SEK 500,000 per quality-adjusted life
year (QALY) gained was used in the PSA. RESULTS: When
including direct medical costs only, the analysis resulted in mean
additional costs of around SEK 200,000 per QALY gained by
using the more effective acid inhibitory treatment strategy
(esomeprazole). The PSA on the probability of esomeprazole
treatment being below a SEK 500,000 per QALY gained thresh-
old supported robustness of a conclusion that esomeprazole
treatment is cost-effective. When work productivity costs were
included, results indicated that the esomeprazole strategy is 
cost-neutral. Extending the time horizon resulted in further cost-
effectiveness advantages for esomeprazole. CONCLUSION:
Esomeprazole 40mgod is cost-effective compared with generic
omeprazole 20mgod in the acute treatment of reﬂux esophagi-
tis in Sweden.
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OBJECTIVES: To determine the relative cost effectiveness of
proton pump inhibitor (PPI) based triple therapy regimens for
the eradication of Helicobacter pylori (H. pylori) in the primary
care setting in Ireland. METHODS: Using decision tree analysis
the expected cost for each H. pylori eradication strategy was
determined from the cost of each treatment option multiplied by
the probability of that option occurring. Only direct costs relat-
ing to the primary care setting such as GP consultation and 
medication costs, extracted from the Monthly Index of Medical
Specialties 2003, were included. Probabilities were obtained
using the GMS prescribing database where all patients who
received amoxycillin, clarithromycin and a PPI in the ERHA
region in 2002 were followed for one year. A broad range of clin-
ical and cost inputs was investigated by sensitivity analysis.
RESULTS: The main outcome measure was the cost per asymp-
tomatic patient for each therapeutic strategy. Depending on the
regimen adopted, 40.8% to 46.1% of patients did not require
any further medication in the year following H. pylori eradica-
tion treatment. The strategy of rabeprazole, amoxycillin and
clarithromycin was the most cost effective option with a cost of
€466 per asymptomatic patient. Two way sensitivity analysis
indicated that the cost of rabeprazole triple therapy and the dura-
tion of rabeprazole maintenance therapy would each have to
increase by 30% before this strategy ceased to be the most cost
effective option. CONCLUSION: This study indicates that the
triple therapy regimen of rabeprazole, amoxycillin and clar-
ithromycin is the most cost effective of the therapeutic strategies
examined for the treatment of H. pylori infection in the com-
munity setting in Ireland.
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OBJECTIVE: To determine the differences in indirect costs and
quality of life between persons affected by Crohn’s Disease (CD)
and those affected by Ulcerative Colitis (UC) as part of a cost of
IBD study in Germany. METHODS: Members of the German
Inﬂammatory Bowel Disease (IBD) Association (DCCV) were
recruited by post to prospectively document their IBD-associated
costs (sick leave, disability pensions, and medical resource use)
in a cost diary over 4 weeks. General demographic information
and IBD history were also reported. Health-Related Quality of
Life (hrQoL) was determined using the EuroQol EQ5-D. Indi-
rect costs were calculated according to national sources using the
human capital approach. RESULTS: Cost diaries were returned
by 483 persons (CD: 241; UC: 242) whose mean age was 42
years and average disease duration 13 years. Productivity losses
were reported by CD (14%) and UC (15%) subjects and average
sick leave was similar (CD: 1.2 days; UC: 1.5 days). However,
more CD (19%) than UC (7%) patients received a disability
pension. The mean 4-week indirect costs for CD were €266
(95%CI: 100, 433) higher than for UC (p < 0.002). The mean
hrQoL of CD subjects according to EuroQol VAS scores was 5
points lower (95%CI: -8.3, -1.7) than for UC subjects (p <
0.004). CONCLUSIONS: In Germany, indirect costs of CD are
signiﬁcantly higher than those of UC and hrQoL of CD patients
is signiﬁcantly lower than of UC patients. For CD, factors
decreasing occupational disability would decrease costs and since
hrQoL is also determined by the ability to work productively,
may improve hrQoL. Factors affecting indirect costs, which
account for a large part of the costs of IBD, can have a large
impact on the overall costs. Furthermore, these ﬁndings indicate
that determinants of costs must be searched for and evaluated
separately for each disease.
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